{"id":723977,"date":"2024-12-11T06:54:01","date_gmt":"2024-12-11T06:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=723977"},"modified":"2024-12-11T06:54:01","modified_gmt":"2024-12-11T06:54:01","slug":"pd1-nonsmall-cell-lung-cancer-treatment-market-2034-ema-pdma-fda-approvals-medication-prevalence-therapies-clinical-trials-and-companies-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pd1-nonsmall-cell-lung-cancer-treatment-market-2034-ema-pdma-fda-approvals-medication-prevalence-therapies-clinical-trials-and-companies-by-delveinsight_723977.html","title":{"rendered":"PD-1 Non-Small Cell Lung Cancer Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1733757960.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"PD-1 Non-Small Cell Lung Cancer Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1733757960.jpeg\" alt=\"PD-1 Non-Small Cell Lung Cancer Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Prevalence, Therapies, Clinical Trials and Companies by DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>PD-1 Non-Small Cell Lung Cancer Treatment Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">PD-1 Non-Small Cell Lung Cancer Companies are Merck, Bristol-Myers Squibb\/Ono Pharmaceutical, Genentech\/ Hoffmann-La Roche, Regeneron\/Sanofi, BeiGene, Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corporation, Akeso Biopharma, Arcus Biosciences, Summit Therapeutics, Seagen, and others.<\/div>\n<p style=\"text-align: justify;\">(Albany, USA) DelveInsight&rsquo;s<strong>&nbsp;&ldquo;PD-1 Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034&Prime;<\/strong>&nbsp;report offers an in-depth understanding of the PD-1 Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the PD-1 Non-Small Cell Lung Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the PD-1 Non-Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">PD-1 Non-Small Cell Lung Cancer Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the PD-1 Non-Small Cell Lung Cancer Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The PD-1 Non-Small Cell Lung Cancer market size is anticipated to grow with a significant&nbsp;<strong>CAGR<\/strong>&nbsp;during the study period (2020-2034)<\/li>\n<li>In April 2024, BeiGene announced that the European Commission (EC) has granted approval for TIZVENI (tislelizumab) as a treatment for NSCLC, covering three indications, including both first- and second-line use.<\/li>\n<li>The PD-(L)1 mNSCLC market size in the US was estimated at approximately&nbsp;<strong>USD 6.2 billion in 2023<\/strong>&nbsp;and is projected to grow further, driven by the introduction of new therapies and expanded indications for existing treatments.<\/li>\n<li>In 2023, the total number of new non-small cell lung cancer (NSCLC) cases in the 7MM was approximately&nbsp;<strong>524,000<\/strong>, and this number is expected to rise throughout the forecast period.<\/li>\n<li>In 2023, the incidence of non-small cell lung cancer (NSCLC) cases in the United States was approximately&nbsp;<strong>56% in males<\/strong>&nbsp;and around&nbsp;<strong>44% in females<\/strong>.<\/li>\n<li>In 2023, the total number of NSCLC cases in the EU4 and the UK was estimated at around<strong>&nbsp;203,220<\/strong>, with Germany recording the highest number of cases among these countries.<\/li>\n<li>The PD-(L)1 biomarker testing rate in the US is approximately<strong>&nbsp;85%<\/strong>. In Japan, the testing rate is higher compared to the EU4 countries and the UK.<\/li>\n<li>In 2023, the total number of PD-(L)1 NSCLC cases in the US was approximately&nbsp;<strong>101,300<\/strong>.<\/li>\n<li><strong>Key PD-1 Non-Small Cell Lung Cancer Companies:<\/strong>&nbsp;Merck, Bristol-Myers Squibb\/Ono Pharmaceutical, Genentech\/ Hoffmann-La Roche, Regeneron\/Sanofi, BeiGene, Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corporation, Akeso Biopharma, Arcus Biosciences, Summit Therapeutics, Seagen, and others<\/li>\n<li><strong>Key PD-1 Non-Small Cell Lung Cancer Therapies:<\/strong>&nbsp;KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), TECENTRIQ (atezolizumab), LIBTAYO (cemiplimab-rwlc), TIZVENI (tislelizumab), GB226, BA-1104, PF-06801591, AZD2936, HX008, Dostarlimab, INCMGA00012, AK-112, Zimberelimab, Ivonescimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, and others<\/li>\n<li>The PD-1 Non-Small Cell Lung Cancer market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage PD-1 Non-Small Cell Lung Cancer pipeline products will significantly revolutionize the PD-1 Non-Small Cell Lung Cancer market dynamics.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">PD-1 Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. It is a category of epithelial lung cancer that includes several subtypes with similar treatment approaches and prognoses.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the PD-1 Non-Small Cell Lung Cancer Market Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/pd-1-non-small-cell-lung-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">https:\/\/www.delveinsight.com\/report-store\/pd-1-non-small-cell-lung-cancer-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The PD-1 Non-Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2020&ndash;2034 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of PD-1 Non-Small Cell Lung Cancer<\/li>\n<li>Prevalent Cases of PD-1 Non-Small Cell Lung Cancer by severity<\/li>\n<li>Gender-specific Prevalence of PD-1 Non-Small Cell Lung Cancer<\/li>\n<li>Diagnosed Cases of Episodic and Chronic PD-1 Non-Small Cell Lung Cancer<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving PD-1 Non-Small Cell Lung Cancer epidemiology trends @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">PD-1 Non-Small Cell Lung Cancer Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the PD-1 Non-Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers PD-1 Non-Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the PD-1 Non-Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>KEYTRUDA (pembrolizumab):<\/strong>&nbsp;Merck<\/li>\n<li><strong>OPDIVO (nivolumab):<\/strong>&nbsp;Bristol-Myers Squibb\/Ono Pharmaceutical<\/li>\n<li><strong>TECENTRIQ (atezolizumab):<\/strong>&nbsp;Genentech\/ Hoffmann-La Roche<\/li>\n<li><strong>LIBTAYO (cemiplimab-rwlc):<\/strong>&nbsp;Regeneron\/Sanofi<\/li>\n<li><strong>TIZVENI (tislelizumab):<\/strong>&nbsp;BeiGene<\/li>\n<li><strong>GB226:<\/strong>&nbsp;Genor Biopharma<\/li>\n<li><strong>BA-1104:<\/strong>&nbsp;Shandong Boan Biotechnology<\/li>\n<li><strong>PF-06801591:<\/strong>&nbsp;Pfizer<\/li>\n<li><strong>AZD2936:<\/strong>&nbsp;AstraZeneca<\/li>\n<li><strong>HX008:<\/strong>&nbsp;Lepu Biopharma<\/li>\n<li><strong>Dostarlimab:<\/strong>&nbsp;GlaxoSmithKline<\/li>\n<li><strong>INCMGA00012:<\/strong>&nbsp;Incyte Corporation<\/li>\n<li><strong>AK-112:<\/strong>&nbsp;Akeso Biopharma<\/li>\n<li><strong>Zimberelimab:<\/strong>&nbsp;Arcus Biosciences<\/li>\n<li><strong>Ivonescimab:<\/strong>&nbsp;Summit Therapeutics<\/li>\n<li><strong>Sasanlimab:<\/strong>&nbsp;Pfizer<\/li>\n<li><strong>Rilvegostomig:<\/strong>&nbsp;AstraZeneca<\/li>\n<li><strong>SGN-PDL1V:<\/strong>&nbsp;Seagen<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major PD-1 Non-Small Cell Lung Cancer market share @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">PD-1 Non-Small Cell Lung Cancer Medication<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Premium-price targeted agents with better clinical profile and expansion of therapies in the first-line expected to drive the growth of NSCLC market<\/li>\n<li>The development of therapies targeting specific mutations are expected to dominate the upcoming market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>PD-1 Non-Small Cell Lung Cancer Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Potential for premium pricing of emerging therapies by showing an edge over current therapies Uptake of potential emerging therapies with better clinical profile, specificity towards mutations occurs in NSCLC and therapies to overcome resistance expected to be fast<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the PD-1 Non-Small Cell Lung Cancer Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2020&ndash;2034<\/strong><\/li>\n<li><strong>Coverage<\/strong>: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key PD-1 Non-Small Cell Lung Cancer Companies:<\/strong>&nbsp;Merck, Bristol-Myers Squibb\/Ono Pharmaceutical, Genentech\/ Hoffmann-La Roche, Regeneron\/Sanofi, BeiGene, Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corporation, Akeso Biopharma, Arcus Biosciences, Summit Therapeutics, Seagen, and others<\/li>\n<li><strong>Key PD-1 Non-Small Cell Lung Cancer Therapies:<\/strong>&nbsp;KEYTRUDA (pembrolizumab), OPDIVO (nivolumab), TECENTRIQ (atezolizumab), LIBTAYO (cemiplimab-rwlc), TIZVENI (tislelizumab), GB226, BA-1104, PF-06801591, AZD2936, HX008, Dostarlimab, INCMGA00012, AK-112, Zimberelimab, Ivonescimab, Sasanlimab, Rilvegostomig, SGN-PDL1V, and others<\/li>\n<li><strong>PD-1 Non-Small Cell Lung Cancer Therapeutic Assessment:<\/strong>&nbsp;PD-1 Non-Small Cell Lung Cancer current marketed and PD-1 Non-Small Cell Lung Cancer emerging therapies<\/li>\n<li><strong>PD-1 Non-Small Cell Lung Cancer Market Dynamics:<\/strong>&nbsp;PD-1 Non-Small Cell Lung Cancer market drivers and PD-1 Non-Small Cell Lung Cancer market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong>&nbsp;SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>PD-1 Non-Small Cell Lung Cancer Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, PD-1 Non-Small Cell Lung Cancer Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about PD-1 Non-Small Cell Lung Cancer companies working in the treatment market, visit @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/pd-1-non-small-cell-lung-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">PD-1 Non-Small Cell Lung Cancer Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. PD-1 Non-Small Cell Lung Cancer Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for PD-1 Non-Small Cell Lung Cancer<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of PD-1 Non-Small Cell Lung Cancer<\/p>\n<p style=\"text-align: justify;\">4. PD-1 Non-Small Cell Lung Cancer Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. PD-1 Non-Small Cell Lung Cancer Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. PD-1 Non-Small Cell Lung Cancer Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. PD-1 Non-Small Cell Lung Cancer Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of PD-1 Non-Small Cell Lung Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. PD-1 Non-Small Cell Lung Cancer Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. PD-1 Non-Small Cell Lung Cancer Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. PD-1 Non-Small Cell Lung Cancer Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. PD-1 Non-Small Cell Lung Cancer Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise PD-1 Non-Small Cell Lung Cancer Market Analysis (2020&ndash;2034)<\/p>\n<p style=\"text-align: justify;\">14. PD-1 Non-Small Cell Lung Cancer Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. PD-1 Non-Small Cell Lung Cancer Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. PD-1 Non-Small Cell Lung Cancer Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; PD-1 Non-Small Cell Lung Cancer Appendix<\/p>\n<p style=\"text-align: justify;\">18. PD-1 Non-Small Cell Lung Cancer Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=pd1-nonsmall-cell-lung-cancer-treatment-market-2034-ema-pdma-fda-approvals-medication-prevalence-therapies-clinical-trials-and-companies-by-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/conference-coverage-services<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=pd1-nonsmall-cell-lung-cancer-treatment-market-2034-ema-pdma-fda-approvals-medication-prevalence-therapies-clinical-trials-and-companies-by-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PD-1 Non-Small Cell Lung Cancer Treatment Market PD-1 Non-Small Cell Lung Cancer Companies are Merck, Bristol-Myers Squibb\/Ono Pharmaceutical, Genentech\/ Hoffmann-La Roche, Regeneron\/Sanofi, BeiGene, Genor Biopharma, Shandong Boan Biotechnology, Pfizer, AstraZeneca, Lepu Biopharma, GlaxoSmithKline, Incyte Corporation, Akeso Biopharma, Arcus Biosciences, Summit &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/pd1-nonsmall-cell-lung-cancer-treatment-market-2034-ema-pdma-fda-approvals-medication-prevalence-therapies-clinical-trials-and-companies-by-delveinsight_723977.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-723977","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/723977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=723977"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/723977\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=723977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=723977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=723977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}